DLI and patient outcome
| UPN . | Age, y* . | Sex, recipient/donor . | Type of donor . | Status at allo-SCT . | Year of allo-SCT . | Time of relapse after allo-SCT, mo . | Tumor lesion at relapse . | Pre-DLI therapy . | Status at DLI . | Time of DLI after relapse, mo . | T-cell dose, × 106/kg . | Response to DLI . | GVHD after DLI (type of cGVHD) . | OS after relapse, mo . | Cause of death . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial . | Total . | |||||||||||||||
| 1 | 56 | M/F | R-PBSC | CR | 2005 | 1.0 | Skin | Oral VP-16 | NE | 8.0 | 5.5 | 5.5 | CR | Progression (extensive) | 45.0 | Infection |
| 2 | 63 | M/M | R-PBSC | CR | 2004 | 2.4 | Skin, hypodermis | Half-dose CHOP | PD | 0.6 | 10.0 | 110.0 | PR | Emergence (extensive) | 16.9 | PD |
| 3 | 41 | M/M | R-BM | PIF | 2004 | 2.8 | CNS | IT | PR | 0.4 | 10.0 | 40.0 | CR | Absent | 19.9 | PD |
| 4 | 53 | M/M | R-BM | PR | 2009 | 100.7 | Skin | RT | SD | 1.0 | 12.0 | 221.0 | CR | Emergence (limited) | 47.7+ | - |
| 5 | 55 | M/F | R-PBSC | Relapse | 2002 | 0.4 | PB, liver, pleural effusion | Half-dose CHOP | PR | 0.9 | 10.0 | 10.0 | CR | Emergence (extensive) | 69.4+ | - |
| 6 | 63 | M/F | R-BM | PR | 2008 | 3.1 | PB | No | PD | 2.3 | 6.9 | 33.0 | PD | Absent | 8.7 | PD |
| 7 | 44 | F/F | R-PBSC | Relapse | 1997 | 10.6 | Bone, liver | No | PD | 1.2 | 5.0 | 15.0 | SD | No progression | 9.2 | PD |
| 8 | 55 | M/M | UR-BM | CR | 2010 | 11.0 | Lymph nodes | No | PD | 1.4 | 5.0 | 65.0 | SD | Progression (extensive) | 5.7 | PD |
| 9 | 53 | M/F | R-BM | PIF | 2009 | 1.1 | Hypodermis | RT | PD | 5.0 | 8.2 | 40.8 | PD | Progression (extensive) | 12.1 | PD |
| UPN . | Age, y* . | Sex, recipient/donor . | Type of donor . | Status at allo-SCT . | Year of allo-SCT . | Time of relapse after allo-SCT, mo . | Tumor lesion at relapse . | Pre-DLI therapy . | Status at DLI . | Time of DLI after relapse, mo . | T-cell dose, × 106/kg . | Response to DLI . | GVHD after DLI (type of cGVHD) . | OS after relapse, mo . | Cause of death . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial . | Total . | |||||||||||||||
| 1 | 56 | M/F | R-PBSC | CR | 2005 | 1.0 | Skin | Oral VP-16 | NE | 8.0 | 5.5 | 5.5 | CR | Progression (extensive) | 45.0 | Infection |
| 2 | 63 | M/M | R-PBSC | CR | 2004 | 2.4 | Skin, hypodermis | Half-dose CHOP | PD | 0.6 | 10.0 | 110.0 | PR | Emergence (extensive) | 16.9 | PD |
| 3 | 41 | M/M | R-BM | PIF | 2004 | 2.8 | CNS | IT | PR | 0.4 | 10.0 | 40.0 | CR | Absent | 19.9 | PD |
| 4 | 53 | M/M | R-BM | PR | 2009 | 100.7 | Skin | RT | SD | 1.0 | 12.0 | 221.0 | CR | Emergence (limited) | 47.7+ | - |
| 5 | 55 | M/F | R-PBSC | Relapse | 2002 | 0.4 | PB, liver, pleural effusion | Half-dose CHOP | PR | 0.9 | 10.0 | 10.0 | CR | Emergence (extensive) | 69.4+ | - |
| 6 | 63 | M/F | R-BM | PR | 2008 | 3.1 | PB | No | PD | 2.3 | 6.9 | 33.0 | PD | Absent | 8.7 | PD |
| 7 | 44 | F/F | R-PBSC | Relapse | 1997 | 10.6 | Bone, liver | No | PD | 1.2 | 5.0 | 15.0 | SD | No progression | 9.2 | PD |
| 8 | 55 | M/M | UR-BM | CR | 2010 | 11.0 | Lymph nodes | No | PD | 1.4 | 5.0 | 65.0 | SD | Progression (extensive) | 5.7 | PD |
| 9 | 53 | M/F | R-BM | PIF | 2009 | 1.1 | Hypodermis | RT | PD | 5.0 | 8.2 | 40.8 | PD | Progression (extensive) | 12.1 | PD |
cGVHD indicates chronic GVHD; R-PBSC, related peripheral blood stem cell; R-BM, related BM; UR-BM, unrelated BM; PB, peripheral blood; PIF, primary induction failure; NE, not evaluated; VP-16, etoposide; IT, intrathecal injection of cytarabine, methotrexate and prednisone; and RT, local radiation therapy.
Age indicates age at time of relapse or progression.